Anisha Wharton

Anisha Wharton serves as Head of Regulatory Affairs at AVEO and brings more than 16 years of global regulatory leadership to support the development, registration and life-cycle management of biologics and pharmaceutical products. Prior to joining AVEO in 2021, Ms. Wharton served as Director, Global Regulatory Affairs – Oncology at Merck & Co., Inc. where she served as the Global Regulatory Lead for early and late-stage clinical development programs for advanced metastatic tumors, women’s cancers, melanoma, and multiple myeloma. While at Merck, Ms. Wharton led a global regulatory team responsible for the approval of a new dosing regimen of KEYTRUDA® across all approved adult indications in over 35 countries. Prior to Merck, she served in global Regulatory Affairs roles of increasing complexity and responsibility at Nektar Therapeutics, InterMune, Inc. (acquired by Roche), InSite Vision, Inc. (acquired by Sun Pharma), and Genentech, Inc. She helped lead a cross functional team in the approval of ESBRIET® and AZASITE®, as well as the development of a global regulatory intelligence database.  Ms. Wharton earned her Bachelor of Science degree from Clark Atlanta University and her Master of Business Administration degree from the University of San Francisco School of Management.

Michael Smith

Michael has extensive experience counseling life sciences companies to achieve clinical and commercial goals while responsibly managing compliance and enforcement risks.  He previously held in-house Legal and Compliance positions at PDL BioPharma, Mylan and Dendreon.  Michael began his legal career with the FDA Drug and Biotechnology practice at an international law firm in Washington, DC.  Prior to his career as an attorney, Michael was a marketer with Procter & Gamble and Bristol-Myers Squibb. Michael earned Juris Doctor and Master of Public Health degrees from the University of Virginia and a Bachelor of Arts degree from the University of Notre Dame.

Kevin Peacock

Kevin Peacock currently serves as AVEO’s Senior Vice President of Marketing. Prior to joining AVEO, he served as both the Vice President, New Product Planning and Business Development at Lycera where he was leading the early commercialization process for Lycera’s novel immune-oncology compounds and in 2015 completed an exclusive strategic collaboration and license with Celgene resulting in $100M in non-dilutive financing. Mr. Peacock also previously served as Vice President, Global Marketing and Business Analytics at Dendreon, where he led the launch of Provenge® in select European countries and managed the US Business Analytics team. Mr. Peacock was Senior Director and Product Champion for Savient Pharmaceuticals while working on Krystexxa® and previously served as Senior Director of New Product Planning at Allos Therapeutics. Prior to that, Mr. Peacock held various roles on the ERBITUX® brand team while at ImClone Systems. Mr. Peacock’s has extensive experience in the oncology commercialization process including marketing, market research, new product planning and product development on the R&D side. Mr. Peacock earned his Bachelor of Administration in Finance and Risk Management from Temple University.  

Manoj Patel, PharmD

Manoj Patel has more than 20 years of experience in the pharmaceutical industry, over 15 of which are directly in the development of oncologic treatments and joins AVEO as Vice President of Program Management. Prior to joining AVEO’s management team, Dr. Patel led the development of several biologics programs as a Project Leader within Teva’s specialty pharma group. Prior to Teva, he held several senior level positions within Project and Program Management as well as Customer Solutions at PRA Health Sciences (now part of ICON) and IQVIA. During his tenure at these CROs, Dr. Patel oversaw the development of oncology treatments for several major pharmaceutical and biotech clients. Prior to IQVIA, he worked at GlaxoSmithKline for more than 10 years across multiple functions that included Clinical Development, Medical Affairs and Project Management. Dr. Patel was also Sr. Director of Program and Alliance Management at ImClone Systems and was involved in the process leading to the ultimate sale of the company to Eli Lilly. Dr. Patel received BS degrees in Chemistry and Pharmacy from the University of North Carolina at Chapel Hill and a Doctorate of Pharmacy from Campbell University.

Jason Noto

Jason Noto brings over 20 years of broad commercial leadership experience to his role as Vice President of Market Access at AVEO Oncology. Prior to joining AVEO, Jason served as Vice President at 1798 Consultants, a strategic market access consultancy specializing in integrated channel strategy, patient support services (HUB), payer contract development and assessment, financial impact analysis, and related Access functions. Earlier, Jason served as Senior Director of Market Access Strategy and Payer Marketing at Amag Pharmaceuticals, leading Payer marketing efforts across all business units totaling >$600M in revenue in 2019.

Prior to his tenure at Amag Pharmaceuticals, Mr. Noto held various launch, in-line, and multi-channel marketing leadership roles of increasing responsibility at Sunovion Pharmaceuticals, Alkermes, and Bristol-Myers Squibb Company. During his career, Mr. Noto has had responsibility for the US commercial launch of various specialty products in oncology, immunology, CNS, & ultra-orphan disease states. Mr. Noto received a B.S. in Business Administration from Le Moyne College and an M.B.A. in finance from the Carroll School of Management at Boston College.

Barbara Natke, Ph.D.

Barbara Natke serves as Vice President of Business Development and bringing more than 20 years of Biotech/Pharma experience to AVEO.  Prior to joining AVEO, Dr. Natke served as the Vice President of Business Development at Samyang Biopharm, USA where she was responsible for creating a pipeline of transformative oncology therapies for the newly established US entity of the Samyang Holdings Corporation.  Prior to Samyang, Dr. Natke served in a variety of roles of increasing responsibility in the Shire/Takeda organization including Scientific Director and Due Diligence Lead.  Before making the transition to the business side of the Pharma industry, Barbara spent 8 years running laboratory groups at Genzyme/Sanofi following her post-doctoral studies at the Massachusetts Institute of Technology.  Dr. Natke holds a PhD in Biochemistry from Boston University School of Medicine and an MBA from Babson College.  

Erick Lucera

Erick Lucera brings to AVEO over twenty years of financial, operational, and investment experience in the biotechnology and medical device industries. He most recently served as chief financial officer of Valeritas, a publicly traded commercial-stage medical technology company focused on developing solutions for people with diabetes, where he led the company through multiple successful public offerings. Prior to Valeritas, Mr. Lucera served as the chief financial officer, treasurer, and secretary of Viventia Bio (acquired by Eleven Biotherapeutics, Inc., now Sesen Bio), a biotechnology company focused on developing targeted protein therapeutics for the treatment of cancer. He also previously served as vice president, corporate development at Aratana Therapeutics, a veterinary biopharmaceutical company, where he helped grow the company’s product pipeline through a series of acquisitions and in-licensing transactions financed through five public and private offerings of nearly $250 million. Previously, Mr. Lucera was vice president, corporate development at Sunshine Heart (now CHF Solution), a medical device manufacturer.

Prior to Sunshine Heart, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital, and as head of the healthcare research team at Independence Investments. He began his career as a staff auditor and accountant at Price Waterhouse & Co. (now PwC). Mr. Lucera holds a CPH from Harvard University, an MS from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera currently holds a CFA designation. Mr. Lucera previously held CMA and CPA designations, which are expired.

Jeb Ledell

Mr. Ledell serves as Chief Operating Officer of AVEO. He joins AVEO from Enzyvant Therapeutics, a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases, where he served as Chief Operating Officer and led key business operations during the recent U.S. Food and Drug Administration approval of RETHYMI®. Prior to Enzyvant, Mr. Ledell served as the Chief operating officer at Compass Therapeutics and Horizon Discovery Group. He was responsible for leading operations at both organizations through several changes in scale. Prior to Horizon, he held multiple technology, operations and development roles at Zalicus Inc. Mr. Ledell holds a BS degree in Chemical Engineering from Worcester Polytechnic Institute.

Vijay Kasturi, MD

Dr. Vijay Kasturi, Vice President, Clinical Development and Medical Affairs, brings more than 25 years of experience establishing and executing global and regional strategies that have brought innovative new treatment options to patients in hematology and oncology. Prior to joining AVEO, Dr. Kasturi was Senior Vice President of Scientific Affairs at FerGene, where he also led both Medical Affairs and Clinical Development. He has also led U.S. Medical Affairs, Oncology for EMD Serono where he had broad leadership responsibilities, including external stakeholder management, evidence generation, medical education and publication strategy. During his time with EMD Serono, Vijay also developed and managed the global medical strategy and launch plan for the company’s anti-PD-L1 agent (avelumab), including indications in Merkel cell, urothelial, and kidney cancer.

Earlier in his career, Dr. Kasturi served as an Assistant Professor of Medicine, Division of Hematology-Oncology  at the University of Massachusetts Medical School and was the program leader for genitourinary oncology at UMass Memorial Cancer Center. He trained in Hematology-Oncology at the National Cancer Institute and worked as an investigator and physician at the National Cancer Institute and at Dartmouth Hitchcock Medical Center.

Danielle Holland

Danielle Holland serves as Vice President of Legal and Corporate Secretary of AVEO. Prior to joining AVEO, Ms. Holland served as an Associate at Skadden, Arps, Slate, Meagher & Flom LLP where she advised public and private clients in a variety of industries in corporate and securities law matters, mergers and acquisitions, governance, corporate finance and other matters. Prior to her legal career, Ms. Holland taught elementary education in New York City through Teach For America. Ms. Holland received a B.A. in International Studies from Boston College and a J.D. from Boston University School of Law.